Dr. Paul Fransen and colleagues from the Physiopharmacology Lab investigated the role of Nitric Oxide (NO) in controlling arterial stiffness. Given the clinical relevance of arterial stiffness as a predictor of cardiovascular risk, NO-signaling pathways could become an attractive pharmacologic target when the underlying mechanisms of arterial stiffening are fully unraveled.
